CN113939514A - 吡咯并嘧啶类化合物及其应用 - Google Patents

吡咯并嘧啶类化合物及其应用 Download PDF

Info

Publication number
CN113939514A
CN113939514A CN202080040813.7A CN202080040813A CN113939514A CN 113939514 A CN113939514 A CN 113939514A CN 202080040813 A CN202080040813 A CN 202080040813A CN 113939514 A CN113939514 A CN 113939514A
Authority
CN
China
Prior art keywords
compound
compounds
isomer
pharmaceutically acceptable
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080040813.7A
Other languages
English (en)
Other versions
CN113939514B (zh
Inventor
钱文远
韦昌青
胡国平
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Jiayue Pharmaceutical Technology Co ltd
Medshine Discovery Inc
Original Assignee
Guangzhou Jiayue Pharmaceutical Technology Co ltd
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Jiayue Pharmaceutical Technology Co ltd, Medshine Discovery Inc filed Critical Guangzhou Jiayue Pharmaceutical Technology Co ltd
Publication of CN113939514A publication Critical patent/CN113939514A/zh
Application granted granted Critical
Publication of CN113939514B publication Critical patent/CN113939514B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

本发明涉及作为JAK抑制剂的吡咯并嘧啶类化合物，以及在制备治疗JAK1或/和JAK2相关疾病的药物中的应用。具体涉及式(Ⅰ)所示化合物、其异构体或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN202080040813.7A 2019-06-05 2020-06-05 吡咯并嘧啶类化合物及其应用 Active CN113939514B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019104870567 2019-06-05
CN201910487056 2019-06-05
PCT/CN2020/094534 WO2020244614A1 (zh) 2019-06-05 2020-06-05 吡咯并嘧啶类化合物及其应用

Publications (2)

Publication Number Publication Date
CN113939514A true CN113939514A (zh) 2022-01-14
CN113939514B CN113939514B (zh) 2022-12-27

Family

ID=73653145

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080040813.7A Active CN113939514B (zh) 2019-06-05 2020-06-05 吡咯并嘧啶类化合物及其应用

Country Status (9)

Country Link
US (1) US20220227788A1 (zh)
EP (1) EP3981769A4 (zh)
JP (1) JP7261428B2 (zh)
KR (1) KR20220017995A (zh)
CN (1) CN113939514B (zh)
AU (1) AU2020288567B2 (zh)
CA (1) CA3140467C (zh)
MX (1) MX2021015056A (zh)
WO (1) WO2020244614A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114591333A (zh) * 2020-12-04 2022-06-07 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的制备方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113372366B (zh) * 2020-12-04 2022-08-30 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的盐、其晶型及其应用
CN113372343B (zh) * 2020-12-04 2022-07-29 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物中间体及其制备方法
WO2022242768A1 (zh) * 2021-05-21 2022-11-24 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的应用
WO2022247885A1 (zh) * 2021-05-26 2022-12-01 正大天晴药业集团股份有限公司 三并杂环类化合物的结晶和盐及其应用
CN114432317A (zh) * 2021-05-31 2022-05-06 广州嘉越医药科技有限公司 吡咯并嘧啶类化合物的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016116025A1 (zh) * 2015-01-20 2016-07-28 南京明德新药研发股份有限公司 Jak抑制剂
WO2016192563A1 (zh) * 2015-05-29 2016-12-08 南京明德新药研发股份有限公司 Janus激酶抑制剂
CN107805259A (zh) * 2017-10-31 2018-03-16 无锡福祈制药有限公司 一种吡咯并嘧啶类化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1382339B1 (en) * 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
US20130040933A1 (en) * 2010-04-27 2013-02-14 Brandon Cash Azaindoles as janus kinase inhibitors
US8993756B2 (en) * 2011-12-06 2015-03-31 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
CN104114553B (zh) * 2011-12-12 2017-03-01 雷迪博士实验室有限公司 作为原肌球蛋白受体激酶(Trk)抑制剂的取代的吡唑并[1,5‑a]吡啶
JP2018199623A (ja) * 2015-10-22 2018-12-20 大正製薬株式会社 含窒素縮合複素環化合物
CN107652308A (zh) * 2017-10-31 2018-02-02 无锡福祈制药有限公司 一种Janus激酶3抑制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016116025A1 (zh) * 2015-01-20 2016-07-28 南京明德新药研发股份有限公司 Jak抑制剂
WO2016192563A1 (zh) * 2015-05-29 2016-12-08 南京明德新药研发股份有限公司 Janus激酶抑制剂
CN107805259A (zh) * 2017-10-31 2018-03-16 无锡福祈制药有限公司 一种吡咯并嘧啶类化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114591333A (zh) * 2020-12-04 2022-06-07 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的制备方法
CN114591333B (zh) * 2020-12-04 2023-08-01 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的制备方法

Also Published As

Publication number Publication date
MX2021015056A (es) 2022-01-18
EP3981769A1 (en) 2022-04-13
EP3981769A4 (en) 2023-07-19
AU2020288567A8 (en) 2023-02-09
CA3140467A1 (en) 2020-12-10
JP2022535838A (ja) 2022-08-10
WO2020244614A1 (zh) 2020-12-10
AU2020288567A1 (en) 2022-02-03
CA3140467C (en) 2023-08-01
AU2020288567B2 (en) 2023-06-15
CN113939514B (zh) 2022-12-27
US20220227788A1 (en) 2022-07-21
JP7261428B2 (ja) 2023-04-20
KR20220017995A (ko) 2022-02-14

Similar Documents

Publication Publication Date Title
CN113939514B (zh) 吡咯并嘧啶类化合物及其应用
US11464780B2 (en) Pyrazolopyrimidine derivative and use thereof
WO2020038457A1 (zh) 作为JAK抑制剂的[1，2，4]三唑并[1，5-a]吡啶类化合物及其应用
CN114728967A (zh) 作为jak抑制剂的三并杂环类化合物及其应用
CN112955454A (zh) 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用
TW202110848A (zh) 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用
CN115210226B (zh) 喹啉类化合物
CN115124526B (zh) 一种吡咯并嘧啶类化合物中间体及其制备方法
CN115066425B (zh) Jak抑制剂在制备治疗jak激酶相关疾病药物中的应用
CN112955453B (zh) 作为选择性Trk抑制剂的吡唑并嘧啶衍生物
CN114761407A (zh) 作为高选择性ros1抑制剂的化合物及其应用
KR20220024199A (ko) Ccr2/ccr5 길항제로서의 헤테로시클로알킬류 화합물
CN114008046A (zh) 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物
CN115667247B (zh) 吡啶类衍生物及其应用
CN115403594A (zh) 含氮三并环类化合物及其应用
CN112752749B (zh) 作为pd-l1免疫调节剂的氟乙烯基苯甲酰胺基化合物
KR102668124B1 (ko) Pd-l1 면역조절제인 비닐 피리딘 카르복사미드 화합물
US20220204507A1 (en) Nitrogen-containing spiro derivative as ret inhibitor
CN118271317A (zh) 1H-吡咯并[2,3-c]吡啶类化合物及其应用
CN117279923A (zh) 六元杂芳并脲环的衍生物及其应用
CN114761405A (zh) 抗hbv的1,7-萘啶类化合物
US20210323979A1 (en) Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective her2 inhibitors and application thereof
TW202200579A (zh) 作為jak抑制劑的三並雜環類化合物及其應用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant